Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Slideshows|August 16, 2019
Rheumatology Network News Roundup
In today's news roundup from Rheumatology Network, we highlight recent findings from ACR Open Rheumatology that examine infection risk in rheumatoid arthritis patients. Plus, we conduct a Q&A from a presentation made at the Rheumatology Nurses Society on alternative treatments for rheumatology conditions.
Advertisement
In today's news roundup from Rheumatology Network, we highlight recent findings from ACR Open Rheumatology that examine infection risk in rheumatoid arthritis patients. Plus, we conduct a Q&A from a presentation made at the Rheumatology Nurses Society on alternative treatments for rheumatology conditions.
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement